CoChat

The KEAP1–NRF2 System as a Molecular Target of Cancer Treatment

Open access

The DOI matches its Crossref record; 114 of the 115 references it cites were found in a registry or an index.

Abstract

The Kelch-like ECH-associated protein 1 (KEAP1)—Nuclear factor erythroid-derived 2-like 2 (encoded by the Nfe2l2 gene; NRF2) system attracts extensive interest from scientists in basic and clinical cancer research fields, as NRF2 exhibits activity as both an oncogene and tumor suppressor, depending on the context. Especially unique and malignant, NRF2-addicted cancers exhibit high levels of NRF2 expression. Somatic mutations identified in the NRF2 or KEAP1 genes of NRF2-addicted cancers cause the stabilization and accumulation of NRF2. NRF2-addicted cancers hijack the intrinsic roles that NRF2 plays in cytoprotection, including antioxidative and anti-electrophilic responses, as well as metabolic reprogramming, and acquire a marked advantage to survive under severe and limited microenvironments. Therefore, NRF2 inhibitors are expected to have therapeutic effects in patients with NRF2-addicted cancers. In contrast, NRF2 activation in host immune cells exerts significant suppression of cancer cell growth, indicating that NRF2 inducers also have the potential to be therapeutics for cancers. Thus, the KEAP1–NRF2 system makes a broad range of contributions to both cancer development and suppression. These observations thus demonstrate that both NRF2 inhibitors and inducers are useful for the treatment of cancers with high NRF2 activity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cancers13010046

Cites

114 of 114 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 The NRF2-sMaf heterodimer regulates cytoprotective gene expression through the CNC-sMaf-binding element (CsMBE) motif. (A) NRF2 forms a heterodimer with sMaf and binds to the CsMBE motif in the nucleus, which is classically referred to as an antioxidant responsive element (ARE)/electrophile responsive element (EpRE) motif. NRF2 positively regulates genes encoding detoxicating enzymes and antioxidative enzymes and negatively regulates genes coding for proinflammatory factors. Ub, ubiquitin. P, phosphorylation. (B) The combination of an E3 ligase and the adaptor for the degradation of NRF2 through ubiquitination: KEAP1–Cul3, βTrCP–Cul1 and WDR23-Cul4 complexes. (C) NRF2 target genes responsible for the drug metabolism, antioxidation, antidiabetes and anti-inflammation. White arrows indicate induction; black bars indicate suppression.
Figure 1 The NRF2-sMaf heterodimer regulates cytoprotective gene expression through the CNC-sMaf-binding element (CsMBE) motif. (A) NRF2 forms a heterodimer with sMaf and binds to the CsMBE motif in the nucleus, which is classically referred to as an antioxidant responsive element (ARE)/electrophile responsive element (EpRE) motif. NRF2 positively regulates genes encoding detoxicating enzymes and antioxidative enzymes and negatively regulates genes coding for proinflammatory factors. Ub, ubiquitin. P, phosphorylation. (B) The combination of an E3 ligase and the adaptor for the degradation of NRF2 through ubiquitination: KEAP1–Cul3, βTrCP–Cul1 and WDR23-Cul4 complexes. (C) NRF2 target genes responsible for the drug metabolism, antioxidation, antidiabetes and anti-inflammation. White arrows indicate induction; black bars indicate suppression.CC BY · PubMed Central
Figure 2 KEAP1–NRF2 system: protein regulation by both proteasome and autophagy.
Figure 2 KEAP1–NRF2 system: protein regulation by both proteasome and autophagy.CC BY · PubMed Central
Figure 3 Monitoring of NRF2 activity in human blood samples. Human NRF2 rSNP, rs6721961, is located within an ARE motif 617 bp upstream from the transcription start site of the NRF2 gene. The minor A/A homozygote diminishes NRF2 gene expression by 40% compared with the C/C homozygote or C/A heterozygote. In diseases including cancers, chronic obstructive pulmonary disease (COPD), autism and multiple sclerosis, NRF2 activity is a potential biomarker for NRF2-inducers including sulforaphane, dimethyl fumarate and bardoxolone methyl (CDDO-Me) that can be monitored by glutathione (GSH) and NRF2 target genes.
Figure 3 Monitoring of NRF2 activity in human blood samples. Human NRF2 rSNP, rs6721961, is located within an ARE motif 617 bp upstream from the transcription start site of the NRF2 gene. The minor A/A homozygote diminishes NRF2 gene expression by 40% compared with the C/C homozygote or C/A heterozygote. In diseases including cancers, chronic obstructive pulmonary disease (COPD), autism and multiple sclerosis, NRF2 activity is a potential biomarker for NRF2-inducers including sulforaphane, dimethyl fumarate and bardoxolone methyl (CDDO-Me) that can be monitored by glutathione (GSH) and NRF2 target genes.CC BY · PubMed Central
Figure 4 Small chemical inhibitors targeting NRF2. (A) NRF2 inhibitors: brusatol, halofuginone and K67. (B) Synthetic lethal drugs for NRF2-addicted cancers: 17-AAG (tanespimycin), 17-DMAG (alvespimycin), IPI-504 (retaspimycin) and mitomycin C.
Figure 4 Small chemical inhibitors targeting NRF2. (A) NRF2 inhibitors: brusatol, halofuginone and K67. (B) Synthetic lethal drugs for NRF2-addicted cancers: 17-AAG (tanespimycin), 17-DMAG (alvespimycin), IPI-504 (retaspimycin) and mitomycin C.CC BY · PubMed Central
Figure 5 Multiple types of chemical inducers for NRF2. (A) Classification of cysteine thiol-directed NRF2-inducers. (B) Electrophilic NRF2-inducers: DMF, sulforaphane and CDDO. (C) NRF2-inducers that inhibit the protein–protein interaction of KEAP1 and NRF2: compound 16 (Cpd16) and the derivative, PRL-295.
Figure 5 Multiple types of chemical inducers for NRF2. (A) Classification of cysteine thiol-directed NRF2-inducers. (B) Electrophilic NRF2-inducers: DMF, sulforaphane and CDDO. (C) NRF2-inducers that inhibit the protein–protein interaction of KEAP1 and NRF2: compound 16 (Cpd16) and the derivative, PRL-295.CC BY · PubMed Central
Figure 6 Hepatocarcinogenesis and NRF2 activation in the resistant hepatocyte model.
Figure 6 Hepatocarcinogenesis and NRF2 activation in the resistant hepatocyte model.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 114 references

Cited by

See all 196

Metadata

Authors
Taguchi, K., & Yamamoto, M.
Affiliations
Tohoku University (JP)
Corresponding author
Yamamoto, Masayuki
Venue
Cancers
Publisher
MDPI AG
Published
2020-12-26
Volume
13
Issue
1
Pages
46
ISSN
2072-6694 (ISSN-L)
OpenAlex
W3114836680
Cited by
195
References
115
Citations by year
2026: 21 · 2025: 34 · 2024: 38 · 2023: 34 · 2022: 46 · 2021: 21
FWCI
2.42
Type
journal article
Language
en
Open access
Locations
  • Cancers (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Ministry of Education, Culture, Sports, Science and Technology (19H05649, 19K07395)
  • Core Research for Evolutional Science and Technology (16gm0410013h0006)
  • Japan Agency for Medical Research and Development (JP20cm0106101)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics, phytochemicals, and oxidative stress
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Redox biology and oxidative stress
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › NF-κB Signaling Pathways
Keywords
Keap1, Nrf2, Nrf2 inhibitors, Nrf2 inducers, oncogene addiction, tumor suppressor, oxidative stress response, metabolic reprogramming, tumor microenvironment, host immune cells, cancer therapy targets

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The KEAP1–NRF2 System as a Molecular Target of Cancer Treatment. https://app.cochat.ai/papers/10.3390/cancers13010046
The paper
Taguchi, K., & Yamamoto, M. (2020). The KEAP1–NRF2 System as a Molecular Target of Cancer Treatment. Cancers. https://doi.org/10.3390/cancers13010046

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.